Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.

NCT NCT00870519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00870519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Lead sponsor
Institute for Neurodegenerative Disorders
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2009
Completion date
December 31, 2010
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease